Former President Trump’s financial filings reveal new Moderna share purchases totaling between $16,001 and $65,000 in March.
Former President Donald Trump reported additional purchases of Moderna (MRNA) shares in March, according to recent financial disclosures. The transactions, dated March 1 and March 16, fall within ranges of $15,001-$50,000 and $1,001-$15,000, respectively.
The filings indicate an expansion of Trump’s existing position in the biotech firm, though exact share counts remain undisclosed. Prior disclosures had shown smaller holdings in Moderna, with no recent sales reported.
Moderna’s stock has seen volatility amid shifting demand for its COVID-19 vaccine and broader biotech sector trends. The company’s market performance has been closely tied to regulatory updates and public health developments.